• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

US Biosimilars Market "Worth $11bn by 2020", Says Report

Article

August 14, 2015.

The US biosimilars market will be worth $11bn by 2020 and biosimilars will account for 4% to 10% of the biologics market total by 2020, according to ReportsnReports' Global & USA Biosimilar Market Analysis to 2021.
With the expected patent expiration of twelve biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market. By 2019, 50% of the biologics market will belong to off-patent drugs, states the report, with the top five biologics targeted by biosimilar developers being Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.

http://www.reportsnreports.com/reports/411918-global-usa-biosimilar-market-analysis-to-2021-biobetters-erythropoietin-epo-human-growth-hormone-hgh-granulocyte-colony-stimulating-factor-g-csf.html

Related Videos
Related Content
UniDoc

UniDoc Brings AI-Powered Health Cube to Alaska

April 17th 2024
Article

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Riccardo Butta

At-Home Patients and AI: Q&A with Riccardo Butta

April 16th 2024
Article

Butta discusses how new technologies are being implemented in at-home devices.

Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Dan Milczarski, Executive Vice President of Process and Technology, CQfluency.

All in on AI is Not the Solution in Life Sciences and Health Care

March 13th 2024
Article

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.